MAP3K14

Across TCGA pan-cancer cohorts, MAP3K14 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP3K14 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAP3K14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP3K14 expression acts as an unfavorable survival marker.

HNSC, ESCA, and CESC are the cancer types where MAP3K14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.208	0.682	.007	24	view →
ESCA	OS	Median	All	0.022	0.701	<.001	12	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.133	0.732	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP3K14–HNSC (DFS)

Open the HNSC breakdown →